Inhibikase Therapeutics Inc. Gains 37.67%
Wed, Jan 24, 2024 at 07:25 PM
Inhibikase Therapeutics Inc. (IKT:NASDAQ) rocketted at $2.96, representing a gain of 37.7%. On Wed, Jan 24, 2024, IKT:NASDAQ hit a New 2-Week High of $2.96. From Wed, Jan 10, 2024, the stock recorded 66.67% Up Days and 70.00% Green Days
About Inhibikase Therapeutics Inc. (IKT:NASDAQ)
Inhibikase Therapeutics Inc is a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related disorders.
Top 10 Gainers:
- Evaxion Biotech A/S (EVAX:NASDAQ), 113.43%
- VS Media Holdings Limited (VSME:NASDAQ), 97.87%
- SciSparc Ltd. (SPRC:NASDAQ), 78.03%
- Getaround Inc. (GETR:NYSE), 76.28%
- CCSC Technology International Holdings Limited (CCTG:NASDAQ), 52.25%
- Kura Oncology, Inc. (KURA:NASDAQ), 46.13%
- Alaunos Therapeutics Inc Com (TCRT:NASDAQ), 45.18%
- Inhibikase Therapeutics Inc. (IKT:NASDAQ), 37.67%
- Esports Technologies Inc. (EBET:NASDAQ), 33.16%
- Akso Health Group (AHG:NASDAQ), 31.89%